Everett Harris & Co. CA Sells 57 Shares of Stryker Co. (NYSE:SYK)

Everett Harris & Co. CA lowered its holdings in Stryker Co. (NYSE:SYK) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,240 shares of the medical technology company’s stock after selling 57 shares during the period. Everett Harris & Co. CA’s holdings in Stryker were worth $1,869,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SYK. Fairfield Bush & CO. bought a new position in shares of Stryker in the 1st quarter valued at about $131,000. Dimensional Fund Advisors LP grew its position in shares of Stryker by 1.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company’s stock valued at $180,182,000 after acquiring an additional 9,026 shares during the period. Prudential PLC bought a new position in shares of Stryker in the 1st quarter valued at about $1,444,000. Sequoia Financial Advisors LLC grew its position in shares of Stryker by 21.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company’s stock valued at $817,000 after acquiring an additional 543 shares during the period. Finally, Zions Bancorporation N.A. grew its position in shares of Stryker by 9.2% in the 1st quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company’s stock valued at $839,000 after acquiring an additional 265 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on SYK. Wells Fargo & Company lifted their price objective on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $360.00 target price on shares of Stryker in a report on Thursday, February 15th. Truist Financial lifted their target price on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a report on Wednesday, January 31st. Roth Mkm lifted their target price on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Citigroup lifted their target price on shares of Stryker from $340.00 to $362.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $331.52.

Stryker Price Performance

Shares of Stryker stock opened at $357.87 on Friday. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The company has a 50-day simple moving average of $343.42 and a two-hundred day simple moving average of $305.60. The stock has a market capitalization of $136.16 billion, a price-to-earnings ratio of 43.38, a price-to-earnings-growth ratio of 2.92 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.27 by $0.19. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the previous year, the company earned $3.00 EPS. Analysts forecast that Stryker Co. will post 11.86 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s payout ratio is presently 38.79%.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. In the last ninety days, insiders sold 212,109 shares of company stock worth $72,845,768. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.